{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:00:53Z","timestamp":1788447653998,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sociedad Latinoamericana de Nefrolog\u00eda e Hipertensi\u00f3n"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13300-026-01854-8","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:06:29Z","timestamp":1773821189000},"page":"499-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type\u00a02 Diabetes and\/or Overweight\/Obesity): A Scoping\u00a0Review"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2852-1241","authenticated-orcid":false,"given":"Jorge","family":"Rico-Fontalvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-4972","authenticated-orcid":false,"given":"Rodrigo","family":"Daza-Arnedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-9328","authenticated-orcid":false,"given":"Alicia","family":"Elbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-8285","authenticated-orcid":false,"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5175-2041","authenticated-orcid":false,"given":"Eliana","family":"Dina-Batlle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-075X","authenticated-orcid":false,"given":"Eduardo","family":"Lorca-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-3968","authenticated-orcid":false,"given":"Thyago Proen\u00e7a","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3253-6363","authenticated-orcid":false,"given":"Vicente","family":"S\u00e1nchez-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2418-6159","authenticated-orcid":false,"given":"Carlos E.","family":"Builes-Monta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"1854_CR1","unstructured":"IDF Diabetes Atlas. 11 ed. Brussels, Belgium: International Diabetes Federation; 2025."},{"issue":"10","key":"1854_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MHA Muskiet","year":"2017","unstructured":"Muskiet MHA, Tonneijck L, Smits MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13(10):605\u201328. https:\/\/doi.org\/10.1038\/nrneph.2017.123.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"1854_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","volume":"105","author":"KC Sourris","year":"2024","unstructured":"Sourris KC, Ding Y, Maxwell SS, et al. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation. Kidney Int. 2024;105(1):132\u201349. https:\/\/doi.org\/10.1016\/j.kint.2023.09.029.","journal-title":"Kidney Int"},{"issue":"19","key":"1854_CR4","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type\u00a02 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"8","key":"1854_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/s2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type\u00a02 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605\u201317. https:\/\/doi.org\/10.1016\/s2213-8587(18)30104-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1854_CR6","unstructured":"Fitch K, Bernstein SJ, Aguilar MD, et al. RAND\/UCLA appropriateness method user's manual: RAND corporation Santa Monica, CA; 2000."},{"issue":"3","key":"1854_CR7","doi-asserted-by":"publisher","first-page":"520","DOI":"10.11124\/jbies-22-00123","volume":"21","author":"D Pollock","year":"2023","unstructured":"Pollock D, Peters MDJ, Khalil H, et al. Recommendations for the extraction, analysis, and presentation of results in scoping reviews. JBI Evid Synth. 2023;21(3):520\u201332. https:\/\/doi.org\/10.11124\/jbies-22-00123.","journal-title":"JBI Evid Synth"},{"issue":"7","key":"1854_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/m18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/m18-0850.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1854_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"1854_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB\u00a02: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1854_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"7650","key":"1854_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"issue":"2","key":"1854_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type\u00a02 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"20","key":"1854_CR14","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type\u00a02 diabetes. N Engl J Med. 2025;392(20):2001\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2501006.","journal-title":"N Engl J Med"},{"issue":"10","key":"1854_CR15","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1007\/s00125-024-06228-y","volume":"67","author":"L Vernstr\u00f8m","year":"2024","unstructured":"Vernstr\u00f8m L, Gullaksen S, S\u00f8rensen SS, et al. Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type\u00a02 diabetes: a post hoc analysis from a 32\u00a0week randomised trial. Diabetologia. 2024;67(10):2175\u201387. https:\/\/doi.org\/10.1007\/s00125-024-06228-y.","journal-title":"Diabetologia"},{"key":"1854_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1240279","volume":"14","author":"MD de Garc\u00eda Lucas","year":"2023","unstructured":"de Garc\u00eda Lucas MD, Caballero I, Fern\u00e1ndez-Garc\u00eda JC, et al. Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type\u00a02 diabetes patients: a multicenter real-world study. Front Endocrinol. 2023;14:1240279. https:\/\/doi.org\/10.3389\/fendo.2023.1240279.","journal-title":"Front Endocrinol"},{"issue":"10","key":"1854_CR17","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.eprac.2024.07.008","volume":"30","author":"JJ Long","year":"2024","unstructured":"Long JJ, Sahi SS, Lemke AI, et al. The use of semaglutide in patients with renal failure-a retrospective cohort study. Endocr Pract. 2024;30(10):963\u20139. https:\/\/doi.org\/10.1016\/j.eprac.2024.07.008.","journal-title":"Endocr Pract"},{"issue":"7","key":"1854_CR18","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058\u201366. https:\/\/doi.org\/10.1038\/s41591-024-03015-5.","journal-title":"Nat Med"},{"issue":"1","key":"1854_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","volume":"31","author":"EM Apperloo","year":"2025","unstructured":"Apperloo EM, Gorriz JL, Soler MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2025;31(1):278\u201385. https:\/\/doi.org\/10.1038\/s41591-024-03327-6.","journal-title":"Nat Med"},{"key":"1854_CR20","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1785384","volume":"19","author":"HL Heerspink","year":"2024","unstructured":"Heerspink HL, Tuttle KR, Pavo I, et al. Tirzepatide reduces albuminuria in patients with T2D: post-hoc pooled analysis of SURPASS 1-5. Diabetol Stoffwechs. 2024;19:S75. https:\/\/doi.org\/10.1055\/s-0044-1785384.","journal-title":"Diabetol Stoffwechs"},{"issue":"8","key":"1854_CR21","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.2337\/dc23-0261","volume":"46","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on cystatin\u00a0C-based kidney function: a SURPASS-4 post hoc analysis. Diabetes Care. 2023;46(8):1501\u20136. https:\/\/doi.org\/10.2337\/dc23-0261.","journal-title":"Diabetes Care"},{"issue":"3","key":"1854_CR22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2337\/dc24-1773","volume":"48","author":"EM Apperloo","year":"2025","unstructured":"Apperloo EM, Tuttle KR, Pavo I, et al. Tirzepatide associated with reduced albuminuria in participants with type\u00a02 diabetes: pooled post hoc analysis from the randomized active- and placebo-controlled SURPASS-1-5 clinical trials. Diabetes Care. 2025;48(3):430\u20136. https:\/\/doi.org\/10.2337\/dc24-1773.","journal-title":"Diabetes Care"},{"issue":"18","key":"1854_CR23","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","volume":"85","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Murakami M, Ou Y, Borlaug BA. Interplay of chronic kidney disease and\u00a0the effects of tirzepatide in patients with heart\u00a0failure, preserved ejection\u00a0fraction, and obesity: the SUMMIT trial. J Am Coll Cardiol. 2025;85(18):1721\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.009.","journal-title":"J Am Coll Cardiol"},{"key":"1854_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/20420188251378216","author":"Y Oe","year":"2025","unstructured":"Oe Y, Nomoto H, Cho KY, et al. Efficacy and safety of tirzepatide in subjects with type\u00a02 diabetes and chronic kidney disease: a prospective, two-arm observational study. Ther Adv Endocrinol Metab. 2025. https:\/\/doi.org\/10.1177\/20420188251378216.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"3","key":"1854_CR25","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/dom.15410","volume":"26","author":"P Karakasis","year":"2024","unstructured":"Karakasis P, Patoulias D, Fragakis N, Klisic A, Rizzo M. Effect of tirzepatide on albuminuria levels and renal function in patients with type\u00a02 diabetes mellitus: a systematic review and multilevel meta-analysis. Diabetes Obes Metab. 2024;26(3):1090\u2013104. https:\/\/doi.org\/10.1111\/dom.15410.","journal-title":"Diabetes Obes Metab"},{"issue":"10193","key":"1854_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type\u00a02 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(19)31150-X.","journal-title":"Lancet"},{"issue":"2","key":"1854_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.34067\/KID.0005852020","volume":"2","author":"KR Tuttle","year":"2021","unstructured":"Tuttle KR, Rayner B, Lakshmanan MC, et al. Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 exploratory analysis. Kidney360. 2021;2(2):254\u201362. https:\/\/doi.org\/10.34067\/KID.0005852020.","journal-title":"Kidney360"},{"key":"1854_CR28","doi-asserted-by":"crossref","unstructured":"Tuttle KR, McKinney TD, Davidson JA, Anglin G, Harper KD, Botros FT. Effects of once-weekly dulaglutide on kidney function in patients with type\u00a02 diabetes in phase\u00a0II and III clinical trials. Diabetes Obes Metab. 2017;19(3):436\u201341.","DOI":"10.1111\/dom.12816"},{"issue":"11","key":"1854_CR29","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1111\/jdi.13877","volume":"13","author":"KI Tsuchida","year":"2022","unstructured":"Tsuchida KI, Taneda S, Yokota I, et al. The renoprotective effect of once-weekly GLP-1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type\u00a02 diabetes and moderate to severe chronic kidney disease (JDDM67). J Diabetes Investig. 2022;13(11):1834\u201341. https:\/\/doi.org\/10.1111\/jdi.13877.","journal-title":"J Diabetes Investig"},{"issue":"4","key":"1854_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"2","key":"1854_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2337\/dc14-2883","volume":"39","author":"MJ Davies","year":"2016","unstructured":"Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type\u00a02 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39(2):222\u201330. https:\/\/doi.org\/10.2337\/dc14-2883.","journal-title":"Diabetes Care"},{"issue":"3","key":"1854_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/dme.12594","volume":"32","author":"BJ von Scholten","year":"2015","unstructured":"von Scholten BJ, Lajer M, Goetze JP, Persson F, Rossing P. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med. 2015;32(3):343\u201352. https:\/\/doi.org\/10.1111\/dme.12594.","journal-title":"Diabet Med"},{"issue":"2","key":"1854_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/dom.12808","volume":"19","author":"BJ von Scholten","year":"2017","unstructured":"von Scholten BJ, Persson F, Rosenlund S, et al. The effect of liraglutide on renal function: a randomized clinical trial. Diabetes Obes Metab. 2017;19(2):239\u201347. https:\/\/doi.org\/10.1111\/dom.12808.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1854_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1620\/tjem.231.57","volume":"231","author":"S Imamura","year":"2013","unstructured":"Imamura S, Hirai K, Hirai A. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type\u00a02 diabetic patients. Tohoku J Exp Med. 2013;231(1):57\u201361. https:\/\/doi.org\/10.1620\/tjem.231.57.","journal-title":"Tohoku J Exp Med"},{"key":"1854_CR35","doi-asserted-by":"crossref","unstructured":"Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type\u00a02 diabetes. N Engl J Med. 2021;385(10):896\u2013907.","DOI":"10.1056\/NEJMoa2108269"},{"issue":"6","key":"1854_CR36","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","volume":"106","author":"V Selvarajah","year":"2024","unstructured":"Selvarajah V, Robertson D, Hansen L, et al. A randomized phase\u00a02b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney Int. 2024;106(6):1170\u201380. https:\/\/doi.org\/10.1016\/j.kint.2024.08.023.","journal-title":"Kidney Int"},{"issue":"7","key":"1854_CR37","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/dom.14712","volume":"24","author":"VER Parker","year":"2022","unstructured":"Parker VER, Hoang T, Schlichthaar H, et al. Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase\u00a02a study of patients with type\u00a02 diabetes and chronic kidney disease. Diabetes Obes Metab. 2022;24(7):1360\u20139. https:\/\/doi.org\/10.1111\/dom.14712.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"1854_CR38","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1159\/000510255","volume":"51","author":"X Wang","year":"2020","unstructured":"Wang X, Zhang H, Zhang Q, et al. Exenatide and renal outcomes in patients with type\u00a02 diabetes and diabetic kidney disease. Am J Nephrol. 2020;51(10):806\u201314. https:\/\/doi.org\/10.1159\/000510255.","journal-title":"Am J Nephrol"},{"issue":"12","key":"1854_CR39","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1111\/dom.14175","volume":"22","author":"AB van der Aart-van der Beek","year":"2020","unstructured":"van der Aart-van der Beek AB, Clegg LE, Penland RC, et al. Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: a post hoc analysis of the EXSCEL trial. Diabetes Obes Metab. 2020;22(12):2493\u20138. https:\/\/doi.org\/10.1111\/dom.14175.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1854_CR40","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/dom.14067","volume":"22","author":"AB van der Aart-van der Beek","year":"2020","unstructured":"van der Aart-van der Beek AB, van Raalte DH, Guja C, et al. Exenatide once weekly decreases urinary albumin excretion in patients with type\u00a02 diabetes and elevated albuminuria: pooled analysis of randomized active controlled clinical trials. Diabetes Obes Metab. 2020;22(9):1556\u201366. https:\/\/doi.org\/10.1111\/dom.14067.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1854_CR41","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","volume":"6","author":"MHA Muskiet","year":"2018","unstructured":"Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type\u00a02 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):859\u201369. https:\/\/doi.org\/10.1016\/S2213-8587(18)30268-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1854_CR42","first-page":"1","volume":"50","author":"Y Muta","year":"2025","unstructured":"Muta Y, Kobayashi K, Toyoda M, et al. Influence of combination therapy with dulaglutide or liraglutide and SGLT2 inhibitors on renal outcomes in patients with type\u00a02 diabetes: a post-hoc analysis of the RECAP study. Tokai J Experiment Clin Med. 2025;50(1):1\u20139.","journal-title":"Tokai J Experiment Clin Med"},{"key":"1854_CR43","doi-asserted-by":"crossref","unstructured":"Dai JW, Lin Y, Li XW, et al. Comparative cardiovascular and renal outcomes of Liraglutide versus dulaglutide in Asian type\u00a02 diabetes patients. Sci Rep. 2024;14(1):27491.","DOI":"10.1038\/s41598-024-79255-9"},{"issue":"1","key":"1854_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0942-x","volume":"18","author":"LE Clegg","year":"2019","unstructured":"Clegg LE, Penland RC, Bachina S, et al. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type\u00a02 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol. 2019;18(1):138. https:\/\/doi.org\/10.1186\/s12933-019-0942-x.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1854_CR45","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.eprac.2024.11.016","volume":"31","author":"YX Cai","year":"2025","unstructured":"Cai YX, Liu FH, Sun JH, Lin CH. The cardiovascular outcomes between liraglutide and dulaglutide among different chronic kidney disease stages in patients with type\u00a02 diabetes. Endocr Pract. 2025;31(3):292\u20137. https:\/\/doi.org\/10.1016\/j.eprac.2024.11.016.","journal-title":"Endocr Pract"},{"key":"1854_CR46","doi-asserted-by":"crossref","unstructured":"Tuttle KR, Bjornstad P, Pruijm M, et al. Mechanistic effects of semaglutide on kidney disease in type\u00a02 diabetes: the REMODEL trial. [Poster]. In press 2025.","DOI":"10.1681\/ASN.2025fdqxb4qe"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01854-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01854-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01854-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:16:54Z","timestamp":1776845814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01854-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1854"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01854-8","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following conflicts of interest. Rodrigo Daza-Arnedo has received speaker honoraria from Novo Nordisk, AstraZeneca, Bayer, and Boehringer Ingelheim. Alicia Elbert has been a member of the speaker boards of AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi, Servier, Raffo, Baliarda, and Adium, and has served as an investigator in studies sponsored by Novo Nordisk, Boehringer Ingelheim, AstraZeneca, and Merck. Ricardo Correa-Rotter has served as a member of the Global Research Committee of FLOW and as national lead for the FLOW and TRIUMPH programs. Eliana Dina-Batlle declares no conflicts of interest. Eduardo Lorca-Herrera has participated in advisory boards for AstraZeneca, Boehringer Ingelheim, Axon Pharma, and Fresenius Medical Care; has received speaker honoraria from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, and Axon Pharma; and has received travel or conference support from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. Thyago Proen\u00e7a de Moraes has received speaker or consulting fees from AstraZeneca, Bayer, Baxter\/Vantive, Boehringer Ingelheim, CSL Vifor, Libbs, Lilly, Merck, Novo Nordisk, Servier, and Takeda. Vicente S\u00e1nchez-Poli has received speaker honoraria from Bayer, Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Novartis, and Janssen. Jorge Rico-Fontalvo has received speaker honoraria from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, Eurofarma, Adium, GSK, MSD, Merck, and Bayer. He has participated in advisory boards for AstraZeneca, Boehringer Ingelheim, Adium, Lilly, Bayer, and Novo Nordisk. Carlos E. Builes-Monta\u00f1o has received consulting and speaking fees from Sanofi, Novo Nordisk, Novartis, Recordati Rare Diseases, Janssen, Chiesi, Abbott, and Boehringer Ingelheim, and is a shareholder of Festina Lente. These disclosures are not necessarily related to the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Ethics approval was not required for this review because it is based exclusively on previously conducted, publicly available studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}